After Novavax announces 'positive' top-line results from its Phase 1/2 clinical trial in older adults. Some famous institute initiates their coverage for NVAX a stock and raises the price target to around 3.50 $.We think Novavx stock NVAX still away undervalue and our price target for the next 20 days is still 3.50 $ and for the next 45 days is 5 $. What about CXRX, XXII, CYTR? If you are interested to know our last update , please join our mail list to receive our rate about those stocks. Important note : We are just a small team of independent traders and uncertified technical chart analysis and we do not have any insider trading or connection at any of these stocks, you own your decision to buy, hold or sell any of these stocks.
Share on Facebook
Share on Twitter
I'm busy working on my blog posts. Watch this space!